BioSpace News Archive

oday, Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, announced its participation in the COVID-19 Evidence Accelerator, an expansive public-private partnership that combines the efforts of academic, government, and private sector organizations by applying real-world data to advance the understanding of COVID-19.

LIFT study to assess safety and efficacy of farnesoid X receptor (FXR) agonist TERN-101 in fatty liver disease patients as an important first step toward combination NASH studies

HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the pre-launch introduction of its new HTG EdgeSeq Pan B-Cell Lymphoma Panel, which is expected to be commercially available for purchase in kit form or as a service in HTG’s VERI/O laboratory starting in July 2020.

CatalYm GmbH, a biopharmaceutical company developing novel cancer immunotherapies, today announced that two abstracts identifying a novel immunoregulatory role for Growth-and-Differentiation Factor 15 (GDF-15) and its effective neutralization by CatalYm’s CTL-002 antibody in cancer have been selected for presentation during the American Association for Cancer Research (AACR) Virtual Annual Meeting II on June 22 – 24, 2020. “ Tumor-derived G

icotec ag announces that the KONG®-TL and the KONG®-C vertebral body replacement systems with the unique Titaniumcoating (Ti-iT®) receive FDA 510(k) clearance in the United States and CE approval in Europe .

Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX), today announced the closing of its underwritten public offering of 15,384,614 shares (including 2,006,688 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares) of its common stock, par value $0.001 per share.

Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, today announced the appointment of Dr. Michael T. Lotze as chief cellular therapy officer (CCO) and Dr. Robert J. Brown as vice president of clinical development.

Premier Inc. (NASDAQ: PINC), a leading healthcare improvement company, today debuted Intersectta®, a new oncology-focused group purchasing organization (GPO) to source cancer and other specialty drugs.

Precision Guard 360, one of the largest and most trusted disinfectant service providers in South Florida, has expanded its offering to include a revolutionary, FDA-approved solution for long-term protection of workplaces, hotels and restaurants from harmful germs.

Mitsubishi Tanabe Pharma Canada, Inc., a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that RADICAVA® is now listed on the New Brunswick Drug Plan formulary.